MedTrace Logo

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

NCT05802836 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-07-10

No results posted yet for this study

Summary

The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.

Conditions

  • Severe Hemophilia A
  • Severe Hemophilia A With Inhibitor
  • Severe Hemophilia A Without Inhibitor

Interventions

OTHER

no interventions

no intervention, only 3 different patients groups

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Chugai Pharma Germany GmbH

    collaborator UNKNOWN

  • Christoph Königs

    lead OTHER

Principal Investigators

  • Christoph Koenigs, PD Dr. Dr · Goethe University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-26
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05802836 on ClinicalTrials.gov